The Effects of Long-Term Oral Benfotiamine Supplementation on Peripheral Nerve Function and Inflammatory Markers in Patients With Type 1 Diabetes

A 24-month, double-blind, randomized, placebo-controlled trial

  1. Kristian F. Hanssen, MD, PHD6,7
  1. 1Diabetes Research Centre, Oslo University Hospital, Oslo, Norway
  2. 2Oslo University Hospital, Oslo, Norway
  3. 3Department of Neurology, Section for Clinical Neurophysiology, Oslo University Hospital-Ullevål, Oslo, Norway
  4. 4Department of Neuroscience, Norwegian University of Science and Technology, Trondheim, Norway
  5. 5Center for Clinical Heart Research, Department of Cardiology B, Oslo University Hospital, Oslo, Norway
  6. 6Faculty of Medicine, University of Oslo, Norway
  7. 7Department of Endocrinology, Oslo University Hospital, Oslo, Norway
  1. Corresponding author: David A. Fraser, david.fraser{at}pronova.com.

Abstract

OBJECTIVE To study the effects of long-term oral benfotiamine supplementation on peripheral nerve function and soluble inflammatory markers in patients with type 1 diabetes.

RESEARCH DESIGN AND METHODS The study randomly assigned 67 patients with type 1 diabetes to receive 24-month benfotiamine (300 mg/day) or placebo supplementation. Peripheral nerve function and levels of soluble inflammatory variables were assessed at baseline and at 24 months.

RESULTS Fifty-nine patients completed the study. Marked increases in whole-blood concentrations of thiamine and thiamine diphosphate were found in the benfotiamine group (both P < 0.001 vs. placebo). However, no significant differences in changes in peripheral nerve function or soluble inflammatory biomarkers were observed between the groups.

CONCLUSION Our findings suggest that high-dose benfotiamine (300 mg/day) supplementation over 24 months has no significant effects upon peripheral nerve function or soluble markers of inflammation in patients with type 1 diabetes.

  • Received September 30, 2011.
  • Accepted January 23, 2012.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ for details.

This Article

  1. Diabetes Care
  1. Supplementary Data
  2. All Versions of this Article:
    1. dc11-1895v1
    2. 35/5/1095 most recent